Bone Biologics raises $3M to extend runway through Q2 2027

Bone Biologics Corp secured approximately $3 million via an at-the-market private placement and intends to fund clinical development and working capital. The funding provokes strategic runway and execution plans for its NB1 spinal fusion therapy through Q2 2027.